title: [Human survivin modified DCs vaccine inhibits laryngeal cancer in vivo and in vitro].
abstract: OBJECTIVE
  Construction of human full-length survivin gene-modified DCs vaccine and observe the biological characteristics and the role of laryngeal cancer treatment.
  
  
  METHODS
  Construction of homologous recombination through the full-length survivin-human adenovirus (pAd-sur), and transfection of immature DCs, induced by access to sophisticated cultivate DCs, the proliferation of activated T lymphocytes; DCs vaccine different groups observed in vitro, in vivo biological activity.
  
  
  RESULTS
  The success in bringing human to build a full-length survivin gene recombinant adenovirus vector pAd-sur; get with the typical characteristics of DCs, the expression level of the surface molecules of up to CD1a 46.2%, CD80 64.2%, CD83 80.5%, HLA-DR 84.3%, vaccine for in vitro cell killing rate 51.5%, compared with the control group, the difference was significant (t = 7.1358, P < 0.01). Gene-modified tumor cell vaccine group was 54.9% of apoptosis and necrosis rate of 21.9%, compared with the control group, the difference was significant (t value was 33.0209 and 17.5057, all P < 0.01).
  
  
  CONCLUSIONS
  Human full-length survivin gene modified, DCs The expression of surface molecules than the rate of gene-modified DCs without a significant increase, with more to stimulate T lymphocyte proliferation, and promote secretion of gamma-IFN; in vivo, in vitro to promote the ability of anti-laryngeal cancer cells.
authors.affiliation: Department Otorhinolaryngology Head and Neck Surgery of the Third Military Medical University Affiliated to Xinqiao Hospital, Chongqing, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.forename: Ming-hong
authors.initials: MH
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Peng
authors.forename: Hua
authors.initials: H
authors.lastname: Yang
authors.forename: Xu-min
authors.initials: XM
authors.lastname: Chan
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D007822:Laryngeal Neoplasms / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D008819:Mice, Nude; D008869:Microtubule-Associated Proteins / Q000235:genetics* / Q000276:immunology*; D030781:Organisms, Genetically Modified; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D019496:Cancer Vaccines; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D000077022:Survivin